Snapshot from Jul 19, 2026 at 14:14 UTC. For live data and tracking: View Live
Events / Technology / Tiziana Doses Last INFORM-MS Patient
Tech clinical trial update

Tiziana Doses Last INFORM-MS Patient

Analysis based on 6 articles · First reported Jun 25, 2026 · Last updated Jun 25, 2026

Sentiment
60
Attention
4
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The successful dosing of the last patient in the INFORM-MS trial by Tiziana Life Sciences is a positive development for the company, potentially increasing investor confidence as it moves closer to topline data readout. This milestone could lead to an upward movement in Tiziana Life Sciences's stock price, especially if the upcoming data is favorable, offering new hope for patients with Multiple sclerosis.

Biotechnology Pharmaceuticals
Event Summary

Tiziana Life Sciences announced that the last patient in its Phase 2a INFORM-MS clinical trial for non-active Secondary Progressive Multiple Sclerosis (na-SPMS) has received their first dose of intranasal foralumab. This randomized, double-blind, placebo-controlled trial is evaluating the safety, tolerability, and efficacy of two doses of intranasal foralumab in up to 48 patients across multiple U.S. sites, including Brigham and Women s Hospital, Johns Hopkins University, Weill Cornell Medicine, and Yale MS Center. Topline data is anticipated in late Q3/early Q4 of 2026 and will be presented at the 10th joint ACTRIMS and ECTRIMS meeting in Toronto, Canada. Tanuja Chitnis, Principal Investigator, and Ivor Elrifi, CEO of Tiziana Life Sciences, expressed optimism about the trial's progress and the potential of intranasal foralumab as a novel therapeutic strategy for na-SPMS.

Entities Involved
stock
Tiziana Life Sciences
Tiziana Life Sciences is the biotechnology company developing intranasal foralumab and is conducting the INFORM-MS Phase 2a clinical trial. The successful dosing of the last patient is a significant milestone for the company, potentially leading to positive future clinical outcomes and increased investor confidence.
Importance 100.0 Sentiment 70.0
per
Tanuja Chitnis
Tanuja Chitnis is the Principal Investigator for the INFORM-MS trial. Her expertise and dedication are instrumental in advancing the trial, and her positive remarks about intranasal foralumab contribute to the event's positive sentiment.
Importance 70.0 Sentiment 50.0
per
Ivor Elrifi
Ivor Elrifi, CEO of Tiziana Life Sciences, expressed enthusiasm for reaching this milestone, highlighting the company's strong execution and the potential of the novel intranasal approach.
Importance 60.0 Sentiment 50.0
cnt
United States
The United States hosts multiple investigational sites for the INFORM-MS trial, indicating the geographical scope of the study.
Importance 10.0 Sentiment 0.0
cnt
Canada
Toronto, Canada, is the planned location for the 10th joint ACTRIMS and ECTRIMS meeting in October 2026, where topline data from the INFORM-MS trial is expected to be presented.
Importance 10.0 Sentiment 0.0
Relationships
Tiziana Life Sciences related ↔ Ivor Elrifi
United States strained-ally ↔ Canada The United States has severely strained its historically close relationship with Canada by imposing sweeping tariffs and
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.